Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 4

Accelerated ART Initiation for PWHIV Who Are Out of Care

NCT06374758 · View on ClinicalTrials.gov ↗

Study Summary

The main purpose of the study is to evaluate the effectiveness, of the ACCELERATE model of care to achieve HIV viral suppression at Week 24. The study will also assess the acceptability, appropriateness, feasibility, and sustainability of the ACCELERATE model of care. The ACCELERATE model combines a standardized method for outreach, the use of telehealth for rapid access to an HIV care provider, a simplified pre-approved HIV regimen, a free 30-day medication starter supply, and re-linkage to medical care.

Interventions

  • OTHER The Accelerate model of care
  • DRUG bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg

Study Locations (4)

Missouri

  • University of Missouri-Columbia — Columbia
  • KC Care Health Center — Kansas City
  • AIDS Project of the Ozarks — Springfield
  • NOVUS Health — St Louis

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2024-04-29
Est. Completion 2026-11-01
Phase Phase 4

Sponsor

University of Missouri-Columbia

275 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06374758

The ClinicalTrials.gov registry entry for NCT06374758 describes a study currently listed as recruiting. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri-Columbia, which has 275 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions — of which The Accelerate model of care is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06374758 reports 4 study locations spanning 1 distinct geographic area — top geographies include Missouri. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06374758 about?

NCT06374758 is a clinical study titled "Accelerated ART Initiation for PWHIV Who Are Out of Care". The main purpose of the study is to evaluate the effectiveness, of the ACCELERATE model of care to achieve HIV viral suppression at Week 24. The study will also assess the acceptability, appropriateness, feasibility, and sustainability of the ACCELERATE model of care. The ACCELERATE model combines a...

What is the current status of trial NCT06374758?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2024-04-29. Estimated completion is 2026-11-01.

What conditions does trial NCT06374758 study?

This clinical trial studies the following conditions: HIV Infections, ART, Noncompliance, Patient. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06374758?

The interventions under investigation include: The Accelerate model of care (OTHER), bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06374758?

This trial is sponsored by University of Missouri-Columbia, which has 275 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06374758 being conducted?

This trial has 4 study locations across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial